Dr. Han has over 15 years of broad-based experience in cancer research and drug development. She has a successful track record of development and execution of strategies across all nonclinical and translational research areas to transition pipeline compounds from pre-IND studies to the early phase clinical trials. Prior to joining Onconano, Dr. Han has led multiple nonclinical and translational programs at Salarius Pharmaceuticals and Beta Cat Pharmaceuticals/Iterion Therapeutics and consulted for several startup companies. She received her Ph.D. degree in Pharmacology from the University of Rochester.